Sector
PharmaceuticalsOpen
₹385.5Prev. Close
₹386.45Turnover(Lac.)
₹344.13Day's High
₹391.7Day's Low
₹374.552 Week's High
₹424.752 Week's Low
₹233.3Book Value
₹101.71Face Value
₹2Mkt Cap (₹ Cr.)
3,109.45P/E
26.14EPS
14.8Divi. Yield
0.2126 May 2023
12:00 AM
Dividend
Dividend Amount: 0.6
Record Date: 15 Sep, 2023
20 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
4 Sep 2023
12:00 AM
AGM
Announcement Date: 04 Sep, 2023
4 Sep 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 16.1 | 16.1 | 14.64 | 14.64 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 683.36 | 599.59 | 253.95 | 134.43 |
Net Worth | 699.46 | 615.69 | 268.59 | 149.07 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 |
|---|---|
Revenue | 385.36 |
yoy growth (%) | |
Raw materials | -128.12 |
As % of sales | 33.24 |
Employee costs | -32.76 |
| Y/e 31 Mar( In .Cr) | Mar-2021 |
|---|---|
Profit before tax | 167.31 |
Depreciation | -6.76 |
Tax paid | -43.71 |
Working capital | |
Other operating items |
| Y/e 31 Mar | Mar-2021 |
|---|---|
Growth matrix (%) | |
Revenue growth | |
Op profit growth | |
EBIT growth | |
Net profit growth |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Satish Waman Wagh
Whole-time Director
Smita Satish Wagh
Whole-time Director
Soloni Satish Wagh
Whole-time Director
Shivani Satish Wagh
Whole-time Director
Balasahab Gulabrao Sawant
Independent Director
Kedar Shankar Karmarkar
Independent Director
Bhairav Manojbhai Chokshi
Independent Director
Dileep Kumar Jain
Independent Director
Dinesh N Modi
Independent Director
Neelam Yashpal Arora
Company Sec. & Compli. Officer
Shweta Shivdhari Singh
Whole-time Director
Manoj Deo Dorlikar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Supriya Lifescience Ltd
Summary
The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.The companys business operations are supported by a modern manufacturing facility located in Parshuram Lo
Read More
What is the Supriya Lifescience Ltd share price today?
The Supriya Lifescience Ltd shares price on N/A is Rs.₹387.5 today.
What is the Market Cap of Supriya Lifescience Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Supriya Lifescience Ltd is ₹3118.71 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Supriya Lifescience Ltd?
The PE and PB ratios of Supriya Lifescience Ltd is 26.14 and 3.82 as of 22 Jul ‘24
What is the 52 Week High and Low of Supriya Lifescience Ltd?
The 52-week high/low is the highest and lowest price at which a Supriya Lifescience Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Supriya Lifescience Ltd is ₹233.9 and ₹424.8 as of 22 Jul ‘24
What is the CAGR of Supriya Lifescience Ltd?
Supriya Lifescience Ltd's CAGR for 5 Years at N/I%, 3 Years at -0.30%, 1 Year at 61.01%, 6 Month at 27.10%, 3 Month at 6.04% and 1 Month at -3.03%.
What is the shareholding pattern of Supriya Lifescience Ltd?
The shareholding pattern of Supriya Lifescience Ltd is as follows:
Promoters - 68.30 %
Institutions - 10.43 %
Public - 21.27 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
